Top Rated Stock: Hidden Gems Outside Hype Zones

Everyone's chasing AI chips and shiny metals—but what if the real asymmetric opportunities are hiding in plain sight, in sectors the crowd has completely written off?

HERE ARE OUR PICKS FOR THIS WEEK!

----------------------------------------------------------

XPeng Inc (XPEV): Pioneering AI-Driven Electric Mobility

XPeng Inc (XPEV) continues its aggressive push into technological innovation, particularly in "autonomous driving" and smart EV ecosystems, positioning itself as a frontrunner in China's competitive electric vehicle landscape. The company emphasizes AI integration, with advancements in end-to-end large models and Turing AI chips enabling enhanced Navigation Guided Pilot (NGP) capabilities for complex urban and highway scenarios.

The latest Q3 2025 earnings demonstrated robust growth: Total revenues reached RMB 20.38 billion, up 101.8% year-over-year and 11.5% sequentially, driven by record vehicle deliveries of 116,007 units—a 149.3% increase from the prior year. Gross margin expanded to 20.1%, reflecting improved vehicle margins at 13.1% amid new model launches like the P7+ and MONA series. Services and other revenues surged 78.1% to RMB 2.33 billion, highlighting ecosystem monetization. Net loss narrowed dramatically to RMB 0.38 billion, down 78.9% year-over-year, with strong cash reserves at RMB 48.33 billion supporting R&D investments. Management guided for Q4 deliveries of 125,000-132,000 units, signaling sustained momentum despite pricing pressures.

Strategic initiatives include global expansion, with partnerships like Volkswagen for VLA 2.0 technology and plans for L4-level autonomy mass production by 2026. Recent updates feature navigation-free driving modes and Robotaxi trials, bolstered by over-the-air enhancements reducing interventions and improving safety.

Outlook:

Market projections remain optimistic: With China's EV penetration accelerating and XPeng's focus on AI differentiation, expect continued delivery growth into triple digits annually, margin expansion toward 25%, and pathway to profitability. In a maturing sector, XPeng offers high-growth exposure for investors betting on intelligent mobility disruption.

Dow Inc (DOW): Materials Science Resilience in Cyclical Recovery

Dow Inc (DOW), a global leader in materials science serving packaging, infrastructure, and consumer applications, has endured consecutive years of significant share price declines amid commodity volatility, demand softness, and tariff-related pressures. These headwinds—now largely priced in—position the company for a potential bottoming and rebound as cost discipline and structural improvements take hold.

Q3 2025 results highlighted ongoing challenges but progress: Net sales of $10.0 billion declined 8% year-over-year due to lower prices across segments, though volume grew modestly. Operating EBIT rose on cost reductions and lower maintenance, while GAAP EPS was $0.08 against an operating loss of $0.19. Sequential sales dipped 1%, offset by efficiency gains. Management advanced $1 billion+ in targeted savings, including European asset rationalizations, enhancing resilience against lingering tariff impacts and macroeconomic uncertainty.

Strategic actions include capital discipline, with delayed projects and footprint optimization freeing cash for returns. Dividend sustainability remains strong, supported by a diversified portfolio in essential end-markets like sustainable packaging and infrastructure.

Outlook:

Projections point to inflection: With tariff effects absorbed, anticipated demand recovery in industrials and consumer segments—coupled with $6.5 billion near-term cash initiatives—could drive EBITDA expansion and earnings growth in 2026. Analysts foresee normalized cycles yielding mid-teens total returns through appreciation and yields. For value-oriented portfolios, DOW embodies cyclical leverage with defensive qualities in an improving environment.

BioCryst Pharmaceuticals Inc (BCRX): Rare Disease Breakthrough Catalyst

BioCryst Pharmaceuticals Inc (BCRX) advances oral therapies for rare diseases, with flagship ORLADEYO driving commercial momentum in hereditary angioedema (HAE) prophylaxis. A landmark regulatory milestone bolsters its trajectory: FDA approval of ORLADEYO oral pellets for preventive treatment in pediatric patients aged 2 to <12 years—making it the first and only targeted oral option for young HAE sufferers, addressing injection burdens and improving adherence. The company has also applied for European approval of this formulation.

Q3 2025 financials underscored execution: ORLADEYO net revenue hit $159.1 million, up 37% year-over-year, fueling GAAP profitability with net income of $12.9 million versus prior losses. Patient retention remained high at over 82% paid rate, supported by expanding prescriber base. Full-year guidance raised to $590-600 million, reflecting sustained demand despite competition.

Interim APeX-P trial data confirmed tolerability and sustained attack reductions in children, reinforcing real-world efficacy. Strong balance sheet post-debt retirement and European divestiture enables pipeline investment without dilution risks.

Outlook:

Projections are compelling: Pediatric label expansion and global filings could accelerate patient adds, pushing peak sales toward $1 billion by 2029. With profitability inflection and multi-bagger potential from HAE market share gains, BCRX represents high-conviction biotech upside amid rising diagnosis rates and limited oral alternatives.